Verify
Independent lab results
Published results from laboratories that tested peptide products they or a study team obtained themselves, failures included. Every row names the laboratory, the method, when the testing was done, what was expected, what was found, and where it was published, so you can check it.
A seller's own certificate is not a source here, and neither is a result nobody can trace. The table shows no prices, no purchase links and no overall score for any seller: a row is one measurement of one product, not a verdict on a company. Data as of October 1, 2026; 12 results. Rules: methodology. Download: lab-results.json.
Results
12 of 12 shown
| Compound | Seller | Measure | Result | Outcome | Method | Laboratory | Tested | Source |
|---|---|---|---|---|---|---|---|---|
| Semaglutide | Biotech Peptides | content | 3.86 mg expected: 3 mg of semaglutide per vial, as labelled | fail | LC-MS | Mass Spectrometry Core Facility, Szentágothai Research Centre, University of Pécs | August 2023 to March 20241 | PMID 39509151; PMID 39093567 |
| Semaglutide | Biotech Peptides | purity | 7.7 % expected: 99%, as stated on the product label or website | inconclusive | LC-MS | Mass Spectrometry Core Facility, Szentágothai Research Centre, University of Pécs | August 2023 to March 20242 | PMID 39509151; PMID 39093567 |
| Semaglutide | Biotech Peptides | sterility | no viable microorganisms expected: sterile, per Ph. Eur. 2.6.1 and USP <71> | pass | USP-71 | PharmaValid Ltd microbiology laboratory, Budapest (ISO 14644-1 certified) | August 2023 to March 20243 | PMID 39509151; PMID 39093567 |
| Semaglutide | Biotech Peptides | endotoxin | <2.1645 EU/mg expected: no acceptance limit is stated in the source for this product | inconclusive | LAL | PharmaValid Ltd microbiology laboratory, Budapest (ISO 14644-1 certified) | August 2023 to March 20244 | PMID 39509151; PMID 39093567 |
| Semaglutide | SemaSpace | content | 2.77 mg expected: 2 mg of semaglutide per vial, as labelled | fail | LC-MS | Mass Spectrometry Core Facility, Szentágothai Research Centre, University of Pécs | August 2023 to March 20245 | PMID 39509151; PMID 39093567 |
| Semaglutide | SemaSpace | purity | 14.37 % expected: 99%, as stated on the product label or website | inconclusive | LC-MS | Mass Spectrometry Core Facility, Szentágothai Research Centre, University of Pécs | August 2023 to March 20246 | PMID 39509151; PMID 39093567 |
| Semaglutide | SemaSpace | sterility | no viable microorganisms expected: sterile, per Ph. Eur. 2.6.1 and USP <71> | pass | USP-71 | PharmaValid Ltd microbiology laboratory, Budapest (ISO 14644-1 certified) | August 2023 to March 20247 | PMID 39509151; PMID 39093567 |
| Semaglutide | SemaSpace | endotoxin | 8.9511 EU/mg expected: no acceptance limit is stated in the source for this product | inconclusive | LAL | PharmaValid Ltd microbiology laboratory, Budapest (ISO 14644-1 certified) | August 2023 to March 20248 | PMID 39509151; PMID 39093567 |
| Semaglutide | USChemLabs | content | 1.34 mg expected: 1 mg of semaglutide per vial, as labelled | fail | LC-MS | Mass Spectrometry Core Facility, Szentágothai Research Centre, University of Pécs | August 2023 to March 20249 | PMID 39509151; PMID 39093567 |
| Semaglutide | USChemLabs | purity | 8.97 % expected: 99%, as stated on the product label or website | inconclusive | LC-MS | Mass Spectrometry Core Facility, Szentágothai Research Centre, University of Pécs | August 2023 to March 202410 | PMID 39509151; PMID 39093567 |
| Semaglutide | USChemLabs | sterility | no viable microorganisms expected: sterile, per Ph. Eur. 2.6.1 and USP <71> | pass | USP-71 | PharmaValid Ltd microbiology laboratory, Budapest (ISO 14644-1 certified) | August 2023 to March 202411 | PMID 39509151; PMID 39093567 |
| Semaglutide | USChemLabs | endotoxin | <2.8658 EU/mg expected: no acceptance limit is stated in the source for this product | inconclusive | LAL | PharmaValid Ltd microbiology laboratory, Budapest (ISO 14644-1 certified) | August 2023 to March 202412 | PMID 39509151; PMID 39093567 |
Notes on each result
- LR-0001: Measured 3.86 mg (SD 0.14) against 3 mg on the label: 28.56% more than labelled, which is the paper's own labelling-accuracy figure. The same method read the genuine Ozempic 1 mg pen at +5.05% over its label. A reader dosing by the label would receive more than intended. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0002: The paper's purity is semaglutide as a share of the whole powder in the vial (3.86 mg of 50.1 mg), not the chromatographic peptide purity a research-grade '99%' claim usually means; the paper found no peptide-like impurities. So the vial is mostly undeclared non-peptide material, and the two percentages measure different things. The measurement stands; the comparison is not like-for-like. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0003: Tested by what the paper calls a direct injection technique, under both pharmacopoeias. The paper reports the lyophilised powder free of viable microorganisms at the time of testing; it does not test the vial after reconstitution or storage. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0004: Reported as below 2.1645 EU/mg by kinetic turbidimetric assay (Ph. Eur. 2.6.14, USP <85>) — an upper bound, not a measured level, although the paper's abstract describes endotoxin as detected in all samples. No limit is stated, so no pass or fail is given here. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0005: Measured 2.77 mg (SD 0.12) against 2 mg on the label: 38.69% more than labelled, which is the paper's own labelling-accuracy figure. The same method read the genuine Ozempic 1 mg pen at +5.05% over its label. A reader dosing by the label would receive more than intended. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0006: The paper's purity is semaglutide as a share of the whole powder in the vial (2.77 mg of 19.3 mg), not the chromatographic peptide purity a research-grade '99%' claim usually means; the paper found no peptide-like impurities. So the vial is mostly undeclared non-peptide material, and the two percentages measure different things. The measurement stands; the comparison is not like-for-like. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0007: Tested by what the paper calls a direct injection technique, under both pharmacopoeias. The paper reports the lyophilised powder free of viable microorganisms at the time of testing; it does not test the vial after reconstitution or storage. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0008: Endotoxin measured at 8.9511 EU/mg by kinetic turbidimetric assay (Ph. Eur. 2.6.14, USP <85>), the highest of the three; the paper says it indicates potential environmental contamination during production. No limit is stated, so no pass or fail is given here. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0009: Measured 1.34 mg (SD 0.07) against 1 mg on the label: 33.58% more than labelled, which is the paper's own labelling-accuracy figure. The same method read the genuine Ozempic 1 mg pen at +5.05% over its label. A reader dosing by the label would receive more than intended. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0010: The paper's purity is semaglutide as a share of the whole powder in the vial (1.34 mg of 14.9 mg), not the chromatographic peptide purity a research-grade '99%' claim usually means; the paper found no peptide-like impurities. So the vial is mostly undeclared non-peptide material, and the two percentages measure different things. The measurement stands; the comparison is not like-for-like. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0011: Tested by what the paper calls a direct injection technique, under both pharmacopoeias. The paper reports the lyophilised powder free of viable microorganisms at the time of testing; it does not test the vial after reconstitution or storage. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
- LR-0012: Reported as below 2.8658 EU/mg by kinetic turbidimetric assay (Ph. Eur. 2.6.14, USP <85>) — an upper bound, not a measured level, although the paper's abstract describes endotoxin as detected in all samples. No limit is stated, so no pass or fail is given here. Named under the sample-control rule: the study team bought this product itself, and the paper reports its results separately from the other products. Test date: The research letter on this study states that test purchases and analytical testing were performed from August 2023 to March 2024; neither paper gives a date for any individual test.
Read and not added
Studies we screened that do not meet the rules yet. They are listed so that leaving them out is visible, not silent.
- Reichel C et al. Gel Electrophoretic Detection of Black Market ACE-031. Drug Test Anal 2025;17(10):1934-1946. A doping-control laboratory bought 14 products sold as ACE-031 from online suppliers in the UK, Europe, China and the USA. None contained ACE-031: twelve held full-length human activin receptor IIB instead of the Fc fusion protein, one held follistatin 344, and one held no protein at all. Not added: The paper gives no date of testing, and a row here needs one. It stays out of the table until a date can be sourced; the finding is reported here because it is published and checkable.